Why and how does light therapy offer neuroprotection in Parkinson’s disease?

Why and how does light therapy offer neuroprotection in Parkinson’s disease?

Red and infrared light (λ = 600–1,070 nm) therapy, known also as photobiomodulation, has been reported to offer neuroprotection and to improve locomotor behaviour in animal models of Parkinson’s disease, from rodents to non-human primates (Rojas and Gonzalez-Lima, 2011; Hamblin, 2016; Johnstone et al., 2016). The neuroprotective aspect of this therapy is particularly relevant; the saving of neurons that would normally die as a result of the parkinsonian degeneration, is without doubt, the “holy-grail” for this, and indeed all other neurodegenerative disorders. The stage is set for translation of light therapy to human patients and there is much hope for benef i cial outcome. In this perspective article, I would like to consider two major issues of light therapy that relate to its neuroprotective function, issues that have intrigued many scientif i c colleagues, together with the wider community.

An answer may lie in the evolutionary process that the response of neurons to light is an “hang-over” from primal invertebrate cells, cells that were once exposed directly to light.ese invertebrate cells may have used the rich and abundant light energy available from the sun to drive intrinsic cellular mechanisms, in much the same way as plants cells use this energy for photosynthesis (Tafur and Mills, 2008). The invertebrate light-responsive mechanisms could have driven normal cell function, together with providing protective“safeguard” measures against pathology or distress.e central neurons of vertebrates, even those evolved to the deepest and darkest corners of the very large primate brain, appear to have kept these light-responsive mechanisms in place.e light therapy used experimentally in animal models of Parkinson’s and other diseases (Rojas and Gonzalez-Lima, 2011; Hamblin, 2016; Johnstone et al., 2016), seems to provide suf fi cient light energy to trigger these primal intrinsic mechanisms within the deep lying central neurons.

In practical terms, evolution thence appears to have rather conveniently presented us with a means by which we can experimentally (and hopefully clinically too) help central neurons to survive pathology and distress (see below). Notwithstanding, this practicality or convenience for our purposes, there could be a little more to the story. In a fascinating twist, although the central neurons of vertebrates have lost their direct light exposure, evolution may have devised a means by which external light energy can still be used to protect them when distressed. Recent studies have reported that light applied to peripheral body structures (e.g., dorsum of body, legs) helps protect - presumably by recruiting a“middle-man” such as the immune and/or stem cell system - distressed central neurons located in the brain (Johnstone et al., 2016). This indirect stimulation of distressed central neurons - although not quite as ef f ective as the direct one -could form part of an evolutionary compensation for their loss of direct light exposure. Taking it a step further, the light-activated immune and/or stem cells from the periphery may well trigger the same intrinsic safeguard mechanisms in distressed central neurons as those triggered by direct light application.ese particular mechanisms will be discussed in detail below.

It should be noted that the ubiquitous light-responsive mechanism apparent in many, if not all, central neurons is distinct from the one operating within the smaller number of opsin-containing neurons, not only within the retina for vision and circadian rhythms, but also within select groups of neurons within the brain itself (encephalopsin, OPN3). The precise function of these brain opsin-containing neurons is not known, but they - like some of their counterparts in the retina - have been suggested to have a role in circadian rhythms (Blackshaw and Snyder, 1999).

The second major issue is “how”? How does light therapy offer neuroprotection, what does it do to make neurons better placed to survive a parkinsonian injury? As touched on above, light may activate intrinsic safeguard mechanisms that the neurons have in place, a le-over from the evolutionary process. When exploring the details of these mechanisms, two general ef f ects of light therapy have been described, the so-called primary and secondary ef f ects (Rojas and Gonzalez-Lima, 2011; Khan and Arany, 2015; Hamblin, 2016).

The primary effects involve light being absorbed by a chromophore, lying within a photoreceptor molecule. A main and well-recognized photoacceptor in mammals is cytochrome c oxidase, lying on the membranes of the mitochondria, the engine room of neurons (Eells et al., 2004; Karu, 2010; Rojas and Gonzalez-Lima, 2011; Khan and Arany, 2015; Hamblin, 2016). This then leads to an increase in both electron transfer in the respiratory chain and in the mitochondrial membrane potential, leading to a surge of adenosine triphosphate energy production. Nitric oxide is released also that, among other things, triggers the vasodilation of nearby blood vessels, increasing blood (and lymphatic) fl ow.ese primary ef f ects are thought to be short-term, principally in operation when the light is directly on the cells (Rojas and Gonzalez-Lima, 2011; Khan and Arany, 2015; Hamblin, 2016). Although cytochrome c oxidase is the best known photoacceptor, absorbing many wavelengths across the near infrared range (600–700 nm and 760–940 nm), it is not the only one. Recently, it has been reported that at a higher wave-length (i.e., 980 nm), temperature/light-gated calcium ion channels on cell mem-branes are stimulated. By contrast, cytochrome c oxidase is not stimulated at this shorter wavelength, but at the longer one (e.g., 810 nm; Hamblin, 2016).ere may well be many other photoacceptors within cells, each of which activate different intrinsic mechanisms.

The secondary effects of light therapy follow on from the primary ones. Following stimulation of cytochrome c oxidase, there is a brief burst of reactive oxygen species, molecules that have important roles in the activation of transcription factors in the nucleus. This then leads to an up-regulation of various stimulatory and protective genes involved in many benef i cial outcomes, including neurogenesis, synaptogenesis and a release of growth factors (e.g., brain derived growth factor).ese secondary ef f ects are thought to be of more long-term benef i t and to operate aer the light exposure has fi nished.ey may well ref l ect the fi ndings that even aer brief light exposure, benef i cial ef f ects are evident for days, weeks or even months thereaer (Rojas and Gonzalez-Lima, 2011; Hamblin, 2016).

In short, light stimulates intrinsic mechanisms to boost energy production within the neuron, to increase local blood fl ow and to activate the expression of genes involved in neuronal survival (Eells et al., 2004; Karu, 2010; Rojas and Gonzalez-Lima, 2011; Hamblin, 2016; Johnstone et al., 2016).ese all contribute to a “healthier” neuron, in a better position to defend and to repair itself from distress. Indeed, it has been suggested that light will aide distressed neurons in any way possible to ensure their survival (Hamblin, 2016). For instance, neurons suf f ering oxidative stress show an increase in reactive oxygen species from dysfunctional mitochondria; in these cases, light exposure decreases the toxic levels of reactive oxygen species, restoring the balance. In addition, when neurons suf f er excitotoxicity and an increase in intracellular calcium, light exposure stimulates a reduction in intracellular calcium, again aiming to restore the balance.

This feature of light therapy - that it stimulates a bespoke intrinsic mechanism that gives the neuron the best chance of survival (Hamblin, 2016) - is exemplified further by findings indicating that patterns of neuronal survival are similar whether the light is applied either at the same time or well aer the injury (Johnstone et al., 2016).at light not only helps to defend and protect healthy neurons against degeneration, but also to repair and rescue distressed neurons after injury. The repair and rescue of distressed neurons are particularly relevant to the clinical reality of Parkinson’s disease, where patients first suffer degeneration and then receive therapeutic intervention. Given the particular functional or “health” state of the neuron, whether it requires protection or rescue, light may, for example, prompt an activation of a certain set of genes to ensure its survival (see above).

In conclusion, although we may never be sure of “why” it works, why light has such an ubiquitous impact on central neurons that normally live and work in the total darkness of the brain - although as scientists we like to ponder - clearer inroads can be made into the “how” it works. It is the more feasible of the two issues raised in this article and, at present, we certainly do have the methods to make the inroads. In particular, the identity of other photoacceptor molecules and different genes, whether stimulatory, protective or for rescue and repair, stimulated with a range of different wavelengths, remains to be discovered. As it stands, light therapy in the experimental setting has been shown to both protect and rescue neurons from degeneration aer parkinsonian injury, something that current therapies in patients do not do; that in itself, should be an incentive for trial in the clinical setting.

Acknowledgements:My thanks to Tenix corp and Salteri family for funding my laboratory work for so many years, to my terrif i c students Victoria Shaw, Cassandra Peoples and Nabil El Massri for being such a pleasure to work with for so long and to Bill Webster and Jonathan Stone for their many insightful comments and stimulating discussions.

John Mitrofanis*

Department of Anatomy F13, University of Sydney, Sydney, Australia

*Correspondence to:John Mitrofanis, Ph.D., john.mitrofanis@sydney.edu.au.

Accepted:2017-03-27

orcid:0000-0002-8857-9808 (John Mitrofanis)

Blackshaw S, Snyder SH (1999) Encephalopsin: a novel mammalian extra-retinal opsin discretely localised in the brain. J Neurosci 19:3681-3690.

Eells JT, Wong-Riley MTT, VerHoeve J, Henry M, Buchman EV, Kane MP, Gould LJ, Das R, Jett M, Hodgson BD, Margolis D, Whelan HT (2004) Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy. Mitochondrion 4:559-567.

Hamblin MR (2016) Shining light on the head: photobiomodulation for brain disorders. BBA Clin 6:113-124.

Johnstone DM, Moro C, Stone J, Benabid AL, Mitrofanis J (2016) Turning on lights to stop neurodegeneration: the potential of near infrared light therapy in Alzheimer’s and Parkinson’s disease. Front Neurosci 9:500.

Karu TI (2010) Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation. IUBMB Life 62:607-610.

Khan I, Arany P (2015) Biophysical approaches for oral wound healing: emphasis on photobiomodulation. Adv Wound Care (New Rochelle) 4:724-737.

Rojas J, Gonzalez-Lima F (2011) Low-level light therapy of the eye and brain. Eye Brain 3:49-67.

Tafur J, Mills PJ (2008) Low-intensity light therapy: exploring the role of redox mechanisms. Photomed Laser Surg 26:323-328.

10.4103/1673-5374.205092

How to cite this article:Mitrofanis J (2017) Why and how does light therapy offer neuroprotection in Parkinson’s disease? Neural Regen Res 12(4):574-575.

Open access statement:This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.